WARF: P160304US01

  • Assigned to WARF as biological material.

Bioluminescent Influenza Virions for High Throughput Screening


Andrew Mehle

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing influenza virions that can be rapidly quantified using standard luciferase assays.
OVERVIEWAssays currently used to detect neutralizing antibodies to influenza virus or measure virion binding to cells, antibodies or receptors require multiple steps. These steps are destructive, low sensitivity and prevent pairing attachment assays with normal infections.
THE INVENTIONA UW–Madison researcher has developed a highly sensitive influenza reporter virus suitable for high throughput assays and in vivo imaging. Moreover, this version of the reporter virus produces bioluminescent virions that can be used to quantitate virion production and virion binding to antibodies, target cells or synthetic receptors. These bioluminescent virions are also ideally suited to rapidly test for the presence of neutralizing antibodies resulting from natural infection or vaccination.

The virus was engineered to express the reporter gene (NanoLuc) and to package copies of the NanoLuc protein into virions, making them bioluminescent. This approach is portable and has been applied to multiple influenza A and B virus strains.
  • Quantification of virus progeny
  • High-throughput quantification of virion binding to cells, receptors or antibodies
  • Rapid detection of neutralizing antibodies in microneutralization assays
  • Enables rapid quantitation using off-the-shelf luciferase assays
  • Ideally suited to measure binding kinetics to cells/synthetic viral receptors
  • Excellent tool for assessing therapies that block virion attachment
  • As the particles are bioluminescent, quantitation can be performed in the absence of infection or gene expression.
STAGE OF DEVELOPMENTThe virus stably maintains the NanoLuc reporter gene and replicates with near wild type kinetics in culture. Bioluminescent virions have been produced and used to quantitate virion attachment and entry.
For More Information About the Inventors
Related Technologies
  • For more information about influenza reporter viruses for real-time in vivo imaging, see WARF reference numbers:
  • P130288US01
  • P160032US01
  • Tran V., Poole D.S., Jeffrey J.J., Sheahan T.P., Creech D., Yevtodiyenko A., Peat A.J., Francis K.P., You S. and Mehle A. 2015. Multi-Modal Imaging with a Toolbox of Influenza A Reporter Viruses. Viruses, 7, 5319-5327.
  • Tran V., Moser L.A., Poole D.S., et al. 2013. Highly Sensitive Real-Time In Vivo Imaging of an Influenza Reporter Virus Reveals Dynamics of Replication and Spread. J. Virol. 87, 13321–13329.
  • Karlsson E.A., Hertz T., Johnson C., et al. 2016. Obesity Outweighs Protection Conferred by Adjuvanted Influenza. mBio. 7, e01144-16.
  • Karlsson E.A., Meliopoulos V.A., Savage C., et al. 2015. Visualizing Real-Time Influenza Virus Infection, Transmission and Protection in Ferrets. Nat. Commun. 6, 6378.
Contact Information
For current licensing status, please contact Jennifer Gottwald at or 608-960-9854.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.